;)
An integrated CDMO–IIT platform for U.S. cell & gene therapy innovators
The Matica Korea IIT Integrated Platform enables early-stage cell and gene therapy developers to generate meaningful clinical data while advancing manufacturing and CMC development through a coordinated U.S.–Korea development pathway. Through a strategic collaboration with the CHA Group, sponsors gain access to Korea’s leading clinical research infrastructure and investigator network alongside Matica Bio’s U.S.-based process development, analytical development, GMP manufacturing, and regulatory support capabilities. Unlike traditional development models that require multiple vendors and complex coordination, the platform provides a single, integrated framework connecting clinical execution and manufacturing strategy. This approach helps sponsors accelerate investigator-initiated trials (IITs), reduce development complexity, and establish a scalable pathway toward future regional and global clinical programs.
Service Offerings
- Data that carries forward
- Korea generated data is directly usable in FDA, EMA & PMDA filings.
- Leverage in BD talks
- High-quality human data anchors valuation and strengthens negotiations with global pharma
- Evidence, not just speed
- Tier-1 sites and experienced CGT investigators produce regulatory-grade, defensible datasets.
- IP stays onshore
- Manufacturing never leaves the U.S., nocross-border IP exposure, BIOSECURE-aligned.